Napo Pharmaceuticals, A Jaguar Health, Inc. Company, Announces Top Line Data For Its Pivotal Phase 3 OnTarget Trial For Prophylaxis Of Diarrhea In Adult Cancer Patients Receiving Targeted Therapy Forthcoming
Portfolio Pulse from Benzinga Newsdesk
Napo Pharmaceuticals, part of Jaguar Health, Inc. (NASDAQ:JAGX), has announced that top line data from its Phase 3 OnTarget trial for crofelemer, a drug for preventing diarrhea in cancer patients, is forthcoming. The trial results are still blinded to the company and key personnel. The trial's abstract has been accepted for presentation at the San Antonio Breast Cancer Symposium in December 2023. Crofelemer is a plant-based drug approved under FDA botanical guidance, and the trial aims to address the unmet need for treatment of chemotherapy-induced overactive bowel (CIOB).
November 21, 2023 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jaguar Health, Inc. is anticipating top line data from a Phase 3 trial of crofelemer for diarrhea prevention in cancer patients. Positive results could significantly impact the company's stock price.
The anticipation of top line data from a pivotal Phase 3 trial is a critical event for Jaguar Health, Inc. Positive results could lead to increased investor confidence and a potential rise in stock price due to the drug's impact on a significant unmet medical need. However, the actual impact will depend on the trial results, which are currently unknown, hence the confidence score is not at the maximum.
CONFIDENCE 75
IMPORTANCE 90
RELEVANCE 100